ATS Corporation (ATS) Stock Forecast and Price Target (2026)

Sell-side coverage follows trading volume and banking relationships, so smaller companies, recent listings, and names outside the major indices often carry little or none. That is the situation with ATS. It says nothing about the quality of the business, but it does mean there is no informed average to anchor to, and that any single target you find elsewhere is one analyst's model rather than a consensus.

The selloff has pushed ATS to about 0.6 times sales and roughly 10 times EBITDA, while trailing GAAP earnings (net income of about 47 million over the last twelve months, after a loss in the March quarter and a near-breakeven June quarter) leave the trailing P/E above 50. The forward multiple near 13 assumes fiscal 2028 EPS recovers to about $1.36, which is a bet on the cost program and the nuclear plus radiopharmaceutical pipeline restoring margin before backlog erosion shows up in revenue. November 4, 2026 brings the next bookings print.

For the fiscal year ending Mar 2027, the 8 analysts publishing estimates on ATS expect earnings of $1.08 per share (-12% on the year before) and revenue of 2.9 billion CAD (-4.0%).

Estimates are the most widely published forecast there is: many more analysts model a company's earnings than publish a price target on it. They are also revised constantly, and the direction of those revisions into a report is often more informative than the level. ATS Corporation next reports on November 4, 2026, which is when these figures get tested against actual results.

Not a published one. Analyst price targets run to about twelve months, occasionally two years, and the firms covering ATS do not put out a 2030 number. Anything presenting one is extrapolating a growth rate rather than reporting research, and a figure produced that way tells you about the assumption chosen, not about the company.

The furthest-out consensus that exists is for the fiscal year ending Mar 2028: analysts expect earnings of $1.38 per share, +28% on the fiscal year ending Mar 2027 estimate of $1.08. Beyond that, nobody publishes estimates, so any later number is an extrapolation.

On the figures we hold as of November 2026, ATS trades at about 54.9 times trailing earnings and 13.9 times forward earnings. A forward multiple below the trailing one means the market expects earnings to grow, and the size of that gap is roughly how much growth is already in the price.

That is the more useful frame for a ten-year question. A share price is the market’s estimate of future cash flows discounted to today, so the multiple is already a statement about growth. The long-horizon question is whether ATS Corporation can deliver what is priced in, and what would have to change for that to break. Both are answerable from the drivers and risks below. A number for 2030 is not.

In short: the drivers cited most often are Life sciences as the durable franchise, Nuclear and energy as the fastest-growing line, The Fixed Cost Transformation Program. The risk cited most often against it is aTS revenue is recognized on long-duration projects, so a handful of delayed customer awards can swing a quarter, and the June 2026 quarter is the live example: bookings down 5.3%, backlog down 8.7%, and a swing from C$24.3 million of net income to a small loss.

Both sides are worked through properly, with the high and low targets used as the bull and bear anchors, on the ATS is it a buy page. This page deliberately stops at the numbers.